FOXO4-DRI is a synthetic senolytic peptide designed to selectively target and clear senescent cells by disrupting the interaction between FOXO4 and p53. In preclinical research, FOXO4-DRI has demonstrated the ability to reduce the burden of senescent cells, decrease age-related inflammation, support tissue function, and promote aspects of healthy aging and cellular rejuvenation in various organ systems.
FOR RESEARCH USE ONLY • NOT FOR HUMAN CONSUMPTION Not evaluated by the FDA • Supplied strictly for laboratory and scientific research purposes only.
FOXO4-DRI is a D-retro-inverso peptide commonly studied in senescence research for its ability to disrupt the FOXO4-p53 interaction, promote p53 redistribution in senescent cell models, and support research into selective senescent cell apoptosis pathways.
Senescent Cell ModelResearch begins with cells displaying senescence-associated signaling and resistance to apoptosis.
FOXO4-p53 InteractionFOXO4 is studied for binding/sequestering p53 in senescent cell models.
FOXO4-DRI DisruptionFOXO4-DRI is studied for disrupting FOXO4-p53 binding interactions.
p53 RelocationResearch models examine p53 nuclear exclusion or redistribution after interaction disruption.
Apoptosis ResearchDownstream models focus on selective apoptosis of senescent cells and senescence-burden reduction.
FOXO4-DRI is a D-retro-inverso peptide studied in cellular senescence research. It is commonly discussed as a senolytic research peptide because of its role in models examining the disruption of FOXO4-p53 interactions and the selective apoptosis of senescent cells.
The strongest way to position FOXO4-DRI is around senescence pathway research, FOXO4-p53 interaction studies, p53 signaling models, senescent cell apoptosis, and SASP-associated pathway research.
Senescent cells are commonly studied for altered cell-cycle regulation, resistance to apoptosis, and secretion of senescence-associated factors. FOXO4-DRI is researched in this context because of its proposed ability to affect survival mechanisms in senescent cell models.
A central research theme is the interaction between FOXO4 and p53. FOXO4-DRI is studied for disrupting that interaction, which may shift p53 behavior in senescent-cell research models.
After FOXO4-p53 disruption, research models examine p53 redistribution and activation of apoptotic pathways in senescent cells. This is the mechanism that makes FOXO4-DRI a senolytic research topic rather than a general longevity supplement.
Because senescent cells can contribute to inflammatory signaling through the senescence-associated secretory phenotype, FOXO4-DRI is often discussed in broader research themes involving SASP, tissue homeostasis, and age-associated cellular dysfunction models.
| Research Feature | FOXO4-DRI | Primary Pathway | Research Significance |
|---|---|---|---|
| Senescent cell targeting | Strong | Senolytic pathway research | High |
| FOXO4-p53 interaction disruption | Strong | Protein-protein interaction disruption | High |
| p53 redistribution research | Strong | p53 signaling and apoptosis models | High |
| Apoptosis of senescent cells | Strong | Selective senescent cell apoptosis models | High |
| SASP-associated pathway research | Moderate to strong | Inflammatory signaling and senescence burden models | Moderate to high |
| Tissue homeostasis models | Moderate | Age-associated cellular dysfunction research | Moderate |
| Longevity pathway research | Supportive | Senescence and cellular aging models | Moderate |
FOXO4-DRI is commonly studied in models involving selective removal or apoptosis of senescent cells.
Research discussions often focus on p53 redistribution, apoptotic signaling, and FOXO4-p53 interaction disruption.
FOXO4-DRI may be discussed in models exploring senescence-associated inflammatory signaling and SASP-related pathways.
Because senescent cells are associated with age-related cellular dysfunction, FOXO4-DRI is often positioned in cellular aging research frameworks.
FOXO4-DRI may appear in research models involving tissue homeostasis, repair capacity, and senescence-burden dynamics.
The peptide is also relevant to research focused on disrupting specific protein-protein interactions such as FOXO4 and p53.
FOXO4-DRI is a D-retro-inverso research peptide commonly studied in senescence models for FOXO4-p53 interaction disruption and selective senescent-cell apoptosis pathways.
It is commonly studied for senolytic pathway research, FOXO4-p53 disruption, p53 signaling, senescent-cell apoptosis, SASP-associated pathways, and cellular aging models.
No. FOXO4-DRI is not desmopressin acetate. Desmopressin is a vasopressin analog. FOXO4-DRI is studied as a senolytic research peptide targeting FOXO4-p53 interaction pathways.
No. FOXO4-DRI is for laboratory research use only. It is not for human consumption, not for animal use, and not intended for medical, therapeutic, diagnostic, or veterinary applications.
| Size | 10 MG |
|---|
Only logged in customers who have purchased this product may leave a review.
This website offers products intended strictly for laboratory and scientific research purposes only.
These products are not for human or animal consumption and are not medical products.
By entering, you confirm that you are 18 years or older and accessing this site for legitimate research purposes only.
Reviews
There are no reviews yet.